Immutep Ltd IMM

SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year. This follows approval from AusIndustry of Immu

SYDNEY, AUSTRALIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a change to the ratio of its American Depositary Shares (“ADSs”), which are quoted on the Nasdaq Global Market under the symbol IMMP. With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Eastern time), the ADS ratio will change from one

Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma (HNSCC) in patients with negative PD-L1 expression (Combined Positive Score (CPS) < 1) and the neoadjuvant setting of soft tissue sarcoma (STS).Root cause analysis following the discontinuation of TACTI-004 has identified subtle analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale. A new manufacturing run of efti at 200 L scale

Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders across four tumour types.IMP761, the only LAG-3 agonist antibody in clinical development, delivered encouraging first-in-human results (presented at EULAR 2026), meeting its primary safety endpoint and showing significant pharmacodynamic activity.Investigation into the futility outcome fro

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the

INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026

First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate statistically significant pharmacodynamic activity at 7 mg/kg in a validated placebo controlled double blinded setting, supporting further clinical investigation in autoimmune diseasesAdditional trial updates will follow in H2 CY2026 SYDNEY, AUSTRALIA, June 04, 2026 (GLOBE NEWSWIRE) -- Immutep Limited

SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic evaluation of 5 clinical trials of eftilagimod alfa (“efti”) an antigen-presenting cell (APC) activator in combination with standard-of-care (SOC) therapies in late-stage cancer patients. In these trials, treatment with 30 mg subcutaneous (SC) efti plus

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader eftilagimod alfa development program are under reviewPhase I IMP761 data demonstrates favourable safety profile; trial progressing to multiple ascending dose phase; data expected at EULAR conference in June CY2026Cash, cash equivalent and term deposit position of A$110.6 million, providing an expected cash

SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive

SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected for poster presentation at the upcoming 2026 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 29 May-2 June 2026 in Chicago, Illinois (United States). The accepted abstract, titled “Impact of eft

We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Immutep Limited is among the oversold stocks to invest in now. TheFly reported on April 15 that IMMP announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to eftilagimod alfa (efti) for the treatment of Soft Tissue […]

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA’s Orphan Drug Designation program is desi

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blin

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple solid tumour indications.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned in